Clinical Trials

201307100

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (RTOG 1216)

201405089

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) Phase II/III Principal Investigator Adkins, Douglas Disease Site Lip, Oral Cavity and…

201503012

A Phase 1/2, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies Phase I/II Principal Investigator Morgensztern, Daniel Disease Site Anus; Bones and Joints; Brain and Nervous System; Breast; Colon;…

201503060

Phase II Trial of Mitomycin C in Patients with Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies Phase II Principal Investigator Oppelt, Peter Disease Site…

201712132

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA…

201802150

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin Phase II/III Principal Investigator Adkins, Douglas…

201802162

Los Tres Paso Trial: Step One Neoadjuvant Palbociclib Monotherapy, Step Two Concurrent Chemoradiation Therapy, and Step Three Adjuvant Palbociclib Monotherapy in Patients with p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma Phase II Principal…

201804077

An open-label, non-randomized, multi-arm, phase II trial to evaluate the efficacy of pembrolizumab combined with cetuximab in patients with recurrent/ metastatic head and neck squamous cell carcinoma (HNSCC) Phase II Principal Investigator Adkins, Douglas Disease…

201805158

Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC) Phase II…

201806100

Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EC-18 in altering the severity and course of oral mucositis in patients being treated with concomitant chemoradiation therapy for cancers of…

201807039

A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Phase II/III Principal Investigator Adkins, Douglas Disease Site Lip, Oral Cavity and Pharynx Learn…

201807170

A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy

201808015

KEYSTROKE: A RANDOMIZED PHASE II STUDY OF PEMBROLIZUMAB (KEYTRUDA®) PLUS STEREOTACTIC RE-IRRADIATION VERSUS SBRT ALONE FOR LOCOREGIONALLY RECURRENT OR SECOND PRIMARY HEAD AND NECK CARCINOMA Phase II Principal Investigator Thorstad, Wade Disease Site Ill-Defined Sites;…

201808045

Phase II Trial of Surgery followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: “The Minimalist Trial (MINT)” Phase II Principal Investigator Adkins, Douglas Disease Site Lip, Oral Cavity and Pharynx Learn…

201809094

A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase I/II Principal Investigator Adkins, Douglas Disease Site Ill-Defined Sites; Larynx; Lip, Oral Cavity…

201810088

A Phase 1B Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination with Nivolumab in Subjects with Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase I…

201902011

Phase II Randomized Trial of Radiotherapy with Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients with Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN Trial) Phase II Principal Investigator Adkins, Douglas Disease…

201903080

A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of DN1508052-01 as a Single Agent when Administered Subcutaneously to Adult Patients with Advanced Solid Tumors Phase I Principal Investigator…

201904155

A phase 1b/2a, open label study to evaluate anti-tumor efficacy and safety of rhIL-7-hyFc (NT-I7) in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory high-risk skin cancers Phase I/II Principal Investigator Ansstas,…

201904206

An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Previously Treated Patients with ASPH+ Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck Phase I/II (Cancer Control) Principal Investigator Adkins,…

201905108

A Phase 1, First-In-Human, Open-label, Dose Escalation and Expansion Study of CUE-101 Monotherapy In Patients with HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Phase I Principal Investigator Adkins, Douglas Disease Site Ill-Defined…

201905156

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma Phase III Principal Investigator Hernandez Aya, Leonel Disease Site Other Skin…

201906051

A Phase II, Open-Label, Multi-dose Study of 89Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Advanced or Metastatic Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the…

201906106

Debio 1143 a SMAC Mimetic in Combination with Nivolumab in Patients Failing Prior PD 1/PD-L1 Treatment: A Basket Trial Phase I/II (Cancer Control) Principal Investigator Morgensztern, Daniel Disease Site Cervix; Colon; Corpus Uteri; Esophagus; Lip,…

201907032

A phase 2 study of combination therapy with an IL-15 superagonist (N-803), off-the-shelf CD16-targeted natural killer cells (haNK), and avelumab without cytotoxic chemotherapy in subjects with Merkel cell carcinoma (MCC) that has progressed on or…

201907077

Sequential therapy with induction TPN followed by Nivolumab with radiation in locoregionally advanced laryngeal and hypopharyngeal cancer Phase II (Cancer Control) Principal Investigator Adkins, Douglas Disease Site Larynx; Lip, Oral Cavity and Pharynx Learn more…

201908135

A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults with Head and Neck Cancer Phase II (Cancer Control) Principal Investigator Adkins, Douglas Disease Site Ill-Defined Sites; Larynx; Lip, Oral Cavity and…

201908206

A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer Phase II/III Principal Investigator Thorstad, Wade Disease Site Esophagus; Lip, Oral Cavity and Pharynx Learn more about…

201911180

A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS Phase I Principal Investigator Adkins, Douglas Disease Site Corpus Uteri; Esophagus;…

201912097

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors Phase I Principal Investigator Adkins, Douglas Disease Site Kidney; Larynx; Lip, Oral…

202001160

A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors Phase I (Cancer Control) Principal Investigator Govindan, Ramaswamy Disease Site…

202006106

A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy Phase II Principal Investigator Adkins,…

202006135

A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head…